Advanced Search:
Equity Index

HYL.BR - HYLORIS

€11.70  0 (0%)

Updated: 07:15 May 12, 2024 EST

Next Session's AI Forecast

98.98%

Avg. Accuracy (AI)

€11.73

Next Week's AI Forecast

0%

Trend's Accuracy (AI)

€12.05

HYLORIS's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

HYLORIS - HISTORICAL DATA 6M

  • Last price

    €11.70

  • Daily change

    €0

  • Previous Close

    €11.7

  • Last Updated

    07:15 May 12, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 -0.47 -0.2 -0.03 -0.02

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 1.22 1.77 1.88 1.8

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
N/A N/A 0% 30.95%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
11.7 -0.26% 11.73 -0.85% 11.83 -3.82% 12.3

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.91 20 0.5 47.64

HYLORIS Technical Analysis News

HYLORIS

Boulevard Patience et Beaujonc N°3/1
Liège 4000
Belgium
32 4 346 02 07
https://hyloris.com

Sectors: Healthcare
Industry: Biotechnology
Description

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. The company provides Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative non-opioid pain management; Tranexamic acid RTU, an antifibrinolytic drug for the formation of blood clots; Miconazole/Domiphen Bromide, a topical synergistic combination treatment for Recurrent Vulvovaginal Candidiasis; AlenuraTM, a first-line drug treatment for acute pain in interstitial cystitis/bladder pain syndrome; and Plecoid Agent IV for the treatment of acute myeloid leukemia and small cell lung cancer. It also offers Atomoxetine, an oral liquid for the treatment of patients with attention deficit hyperactivity disorder; HY-029, a liquid formulation of an antiviral drug to treat viral infections; HY-083, a nasal spray for the treatment of idiopathic rhinitis; and HY-088, an oral liquid that treats hypophosphatemia. The company was incorporated in 2012 and is headquartered in Liège, Belgium.

Corporate Governance

Hyloris Pharmaceuticals SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.